The PBS listings for inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) have been extended from October include to include patients with relapsed or refractory (R/R) Philadelphia chromosome positive (Ph+) B-cell precursor acute lymphocytic leukaemia (B-ALL). Until now the the two drugs have been recommended for treatment of R/R Philadelphia chromosome negative (Ph-) CD22 positive B-ALL patients. ...
Immunotherapies get PBS listing extended for Philadelphia positive B-ALL
29 Sep 2019